Reply to comment on “The natural history of progressive fibrosing interstitial lung diseases”

Kevin K. Brown, Rozsa Schlenker-Herceg, Athol U. Wells

Source: Eur Respir J, 56 (6) 2003967; 10.1183/13993003.03967-2020
Journal Issue: December
Disease area: Interstitial lung diseases

Congress or journal article abstractFull text journal articlePDF journal article, handout or slides

Rating: 0
You must login to grade this presentation.

Share or cite this content

Citations should be made in the following way:
Kevin K. Brown, Rozsa Schlenker-Herceg, Athol U. Wells. Reply to comment on “The natural history of progressive fibrosing interstitial lung diseases”. Eur Respir J, 56 (6) 2003967; 10.1183/13993003.03967-2020

You must login to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.

Member's Comments

No comment yet.
You must Login to comment this presentation.


Related content which might interest you:
Comment on “The natural history of progressive fibrosing interstitial lung diseases”
Source: Eur Respir J, 56 (6) 2003508; 10.1183/13993003.03508-2020
Year: 2020



The natural history of progressive fibrosing interstitial lung diseases
Source: Eur Respir J, 55 (6) 2000085; 10.1183/13993003.00085-2020
Year: 2020



Treatment of progressive fibrosing interstitial lung diseases: a milestone in the management of interstitial lung diseases
Source: Eur Respir Rev, 28 (153) 190109; 10.1183/16000617.0109-2019
Year: 2019



Prevalence of progressive fibrosing interstitial lung disease
Source: International Congress 2018 – Pitfalls in the diagnosis and management of rare diffuse parenchymal lung diseases (DPLDs)
Year: 2018


Incidence and prevalence of idiopathic pulmonary fibrosis: review of the literature
Source: Eur Respir Rev 2012 21: 355-361
Year: 2012



Genetic susceptibilty and manifestation of progressive fibrosing interstitial lung diseases.
Source: Virtual Congress 2020 – New clinical insights into idiopathic pulmonary fibrosis
Year: 2020




Clinicoradiological features of chronic fibrosing interstitial pneumonia with smoking history
Source: Annual Congress 2009 - Pathogenesis of pulmonary fibrosis
Year: 2009


Smoking-related interstitial lung diseases: a concise review
Source: Eur Respir J 2001; 17: 122-132
Year: 2001



Relevance of the expert ILD clinical-radiological evaluation of referred cases to the MDT
Source: International Congress 2016 – Clinical aspects of ILD
Year: 2016


Idiopathic nonspecific interstitial pneumonia: an interstitial lung disease associated with autoimmune disorders?
Source: Eur Respir J 2011; 38: 384-391
Year: 2011



Genetics of fibrosing lung diseases
Source: Eur Respir J 2005; 25: 915-927
Year: 2005



Clinical efficacy of pirfenidone in patients with severe fibrosing interstitial pneumonia
Source: International Congress 2015 – Treatment of IPF
Year: 2015


Potential of nintedanib in treatment of progressive fibrosing interstitial lung diseases
Source: Eur Respir J, 54 (3) 1900161; 10.1183/13993003.00161-2019
Year: 2019



Interstitial lung diseases: course report
Source: Breathe, 14 (3) 184; 10.1183/20734735.019718
Year: 2018



Interstitial lung diseases: course report
Source: Breathe, 15 (4) 270; 10.1183/20734735.0259-2019
Year: 2019



Chronic hypersensitivity pneumonitis with familial history of interstitial lung disease
Source: Annual Congress 2010 - Pathogenesis of diffuse parenchymal lung disease
Year: 2010


Interstitial lung diseases: course report
Source: Breathe 2016; 12: 213-215
Year: 2016


How should we approach the treatment of progressive fibrosing ILDs?
Source: International Congress 2019 – New Horizons in The Treatment of Pulmonary Fibrosis
Year: 2019

Rare interstitial lung diseases of environmental origin
Source: Eur Respir Mon 2011; 54: 301-316
Year: 2011


Genetics variants in familial interstitial pneumonia and progressive fibrosing interstitial lung disease (PF-ILD)
Source: Virtual Congress 2021 – Genetics and translational aspects of idiopathic pulmonary fibrosis
Year: 2021